Adrian Schmidt

A universal anti‐Xa assay for rivaroxaban, apixaban, and edoxaban measurements: method validation, diagnostic accuracy and external validation

Guido Willekens, Jan–Dirk Studt, Adriana Méndez et al. · British Journal of Haematology · 2021 · 46 citations · Full text

Pharmacy, Pharmaceutical Analysis, Pharmacology +13

A machine-learning model for reducing misdiagnosis in heparin-induced thrombocytopenia: a prospective, multicenter, observational study

Henning Nilius, Adam Cuker, S. Haug et al. · EClinicalMedicine · 2022 · 33 citations · Full text

Medicine, Clinical Sciences, Hematology +16

Trends of classification, incidence, mortality, and survival of MDS patients in Switzerland between 2001 and 2012

Nicolas Bonadies, Anita Feller, Alicia Rovó et al. · Cancer Epidemiology · 2017 · 32 citations

Medicine, Internal Medicine, Clinical Classification Systems +4

Expert recommendation from the Swiss Amyloidosis Network (SAN) for systemic AL-amyloidosis

Rahel Schwotzer, Andreas J. Flammer, Sabine Gerull et al. · Swiss Medical Weekly · 2020 · 22 citations · Full text

Life Sciences, Pharmacology, Pharmacotherapy +13

Accuracy of a Single, Heparin-Calibrated Anti-Xa Assay for the Measurement of Rivaroxaban, Apixaban, and Edoxaban Drug Concentrations: A Prospective Cross-Sectional Study

Tamana Meihandoest, Jan–Dirk Studt, Adriana Méndez et al. · Frontiers in Cardiovascular Medicine · 2022 · 18 citations · Full text

Medicine, Pharmacology, Clinical Pharmacology +2